Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells with Sintilimab and Chemotherapy in Stage IV NSCLC
NCT04836728Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cytokine-induced killer cells in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Mar 2021; status: active, not recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04836728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836728.